Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of BMS-986177 for prevention of new ischemic stroke or covert brain infarction after acute ischemic stroke or TIA
jRCT2080225014Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke, transient ischaemic attack (TIA), cerebral arteriosclerosis and 1 more comparing BMS-986177 + aspirin + clopidogrel with Placebo + aspirin + clopidogrel (2 arms). Started Jan 2020; status: completed.
02
Drugs
milvexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)cerebral arteriosclerosisCarotid artery disease (CAD)
Beyond the preview
Go deeper on jRCT2080225014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225014.